JP2013516489A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013516489A5 JP2013516489A5 JP2012548193A JP2012548193A JP2013516489A5 JP 2013516489 A5 JP2013516489 A5 JP 2013516489A5 JP 2012548193 A JP2012548193 A JP 2012548193A JP 2012548193 A JP2012548193 A JP 2012548193A JP 2013516489 A5 JP2013516489 A5 JP 2013516489A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- modified
- composition according
- compound
- modified oligonucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 108091034117 Oligonucleotide Proteins 0.000 claims 13
- 239000002777 nucleoside Substances 0.000 claims 11
- 150000001875 compounds Chemical class 0.000 claims 10
- 241001465754 Metazoa Species 0.000 claims 6
- 125000003835 nucleoside group Chemical group 0.000 claims 6
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 5
- 102100025668 Angiopoietin-related protein 3 Human genes 0.000 claims 4
- 101000693085 Homo sapiens Angiopoietin-related protein 3 Proteins 0.000 claims 4
- 230000002503 metabolic effect Effects 0.000 claims 3
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical group CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 208000016097 disease of metabolism Diseases 0.000 claims 2
- 208000030159 metabolic disease Diseases 0.000 claims 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 claims 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29360410P | 2010-01-08 | 2010-01-08 | |
| US61/293,604 | 2010-01-08 | ||
| PCT/US2011/020606 WO2011085271A2 (en) | 2010-01-08 | 2011-01-07 | Modulation of angiopoietin-like 3 expression |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015156939A Division JP6440592B2 (ja) | 2010-01-08 | 2015-08-07 | アンジオポエチン様３発現の調節 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013516489A JP2013516489A (ja) | 2013-05-13 |
| JP2013516489A5 true JP2013516489A5 (enExample) | 2013-08-08 |
| JP5822845B2 JP5822845B2 (ja) | 2015-11-25 |
Family
ID=44306180
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012548193A Expired - Fee Related JP5822845B2 (ja) | 2010-01-08 | 2011-01-07 | アンジオポエチン様３発現の調節 |
| JP2015156939A Expired - Fee Related JP6440592B2 (ja) | 2010-01-08 | 2015-08-07 | アンジオポエチン様３発現の調節 |
| JP2017098842A Pending JP2017165765A (ja) | 2010-01-08 | 2017-05-18 | アンジオポエチン様３発現の調節 |
| JP2020032712A Pending JP2020100654A (ja) | 2010-01-08 | 2020-02-28 | アンジオポエチン様３発現の調節 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015156939A Expired - Fee Related JP6440592B2 (ja) | 2010-01-08 | 2015-08-07 | アンジオポエチン様３発現の調節 |
| JP2017098842A Pending JP2017165765A (ja) | 2010-01-08 | 2017-05-18 | アンジオポエチン様３発現の調節 |
| JP2020032712A Pending JP2020100654A (ja) | 2010-01-08 | 2020-02-28 | アンジオポエチン様３発現の調節 |
Country Status (9)
| Country | Link |
|---|---|
| US (5) | US8653047B2 (enExample) |
| EP (2) | EP3421040A1 (enExample) |
| JP (4) | JP5822845B2 (enExample) |
| CN (3) | CN111700901A (enExample) |
| AU (1) | AU2011203986C1 (enExample) |
| CA (1) | CA2786071C (enExample) |
| DK (1) | DK2521556T3 (enExample) |
| ES (1) | ES2677969T3 (enExample) |
| WO (1) | WO2011085271A2 (enExample) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG171914A1 (en) | 2008-12-02 | 2011-07-28 | Chiralgen Ltd | Method for the synthesis of phosphorus atom modified nucleic acids |
| EP2451461A4 (en) | 2009-07-06 | 2013-05-29 | Ontorii Inc | NOVEL NUCLEIC ACID PRODRUGS AND METHOD OF USE THEREOF |
| CN111700901A (zh) * | 2010-01-08 | 2020-09-25 | Ionis制药公司 | 血管生成素样3表达的调节 |
| DK2620428T3 (da) | 2010-09-24 | 2019-07-01 | Wave Life Sciences Ltd | Asymmetrisk hjælpegruppe |
| JO3412B1 (ar) | 2011-06-17 | 2019-10-20 | Regeneron Pharma | أجسام مضادة ل angptl3 واستخداماتها |
| EP3444348A1 (en) | 2011-06-21 | 2019-02-20 | Alnylam Pharmaceuticals, Inc. | Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof |
| US9605019B2 (en) | 2011-07-19 | 2017-03-28 | Wave Life Sciences Ltd. | Methods for the synthesis of functionalized nucleic acids |
| EP3640332A1 (en) | 2011-08-29 | 2020-04-22 | Ionis Pharmaceuticals, Inc. | Oligomer-conjugate complexes and their use |
| WO2013070786A1 (en) | 2011-11-07 | 2013-05-16 | Isis Pharmaceuticals, Inc. | Modulation of tmprss6 expression |
| IL303831A (en) * | 2011-11-18 | 2023-08-01 | Alnylam Pharmaceuticals Inc | Adapted RNAI factors |
| DK2872485T3 (da) | 2012-07-13 | 2021-03-08 | Wave Life Sciences Ltd | Asymmetrisk hjælpegruppe |
| JP6246121B2 (ja) | 2012-07-13 | 2017-12-13 | 株式会社新日本科学 | キラル核酸アジュバント |
| CN112007045B (zh) | 2012-07-13 | 2026-01-06 | 波涛生命科学有限公司 | 手性控制 |
| SG10201804331TA (en) | 2012-11-15 | 2018-07-30 | Roche Innovation Ct Copenhagen As | Oligonucleotide conjugates |
| US20150368642A1 (en) | 2013-01-30 | 2015-12-24 | Hoffmann-La Roche Inc. | Lna oligonucleotide carbohydrate conjugates |
| CA2921162A1 (en) | 2013-05-01 | 2014-11-06 | Ionis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
| TWI657819B (zh) * | 2013-07-19 | 2019-05-01 | 美商Ionis製藥公司 | 用於調節τ蛋白表現之組合物 |
| HUE052243T2 (hu) * | 2013-12-24 | 2021-04-28 | Ionis Pharmaceuticals Inc | Az angiopoietin-szerû 3 expressziójának modulációja |
| WO2015108048A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
| EP3095461A4 (en) | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator |
| US10322173B2 (en) | 2014-01-15 | 2019-06-18 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent |
| KR102423317B1 (ko) | 2014-01-16 | 2022-07-22 | 웨이브 라이프 사이언시스 리미티드 | 키랄 디자인 |
| MX382230B (es) * | 2014-05-01 | 2025-03-13 | Ionis Pharmaceuticals Inc | Composiciones y metodos para modular la expresion de similar a la angiopoyetina tipo 3. |
| US10570169B2 (en) | 2014-05-22 | 2020-02-25 | Ionis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
| CA2979998A1 (en) * | 2015-03-20 | 2016-09-29 | Protiva Biotherapeutics, Inc. | Compositions and methods for treating hypertriglyceridemia |
| HK1249140A1 (zh) | 2015-04-03 | 2018-10-26 | Ionis Pharmaceuticals, Inc. | 用於调节tmprss6表达的化合物和方法 |
| KR20250005546A (ko) | 2015-04-13 | 2025-01-09 | 알닐람 파마슈티칼스 인코포레이티드 | 안지오포이에틴-유사 3(angptl3) irna 조성물 및 이의 이용 방법 |
| EP3370713A4 (en) * | 2015-11-06 | 2019-10-23 | Gemphire Therapeutics Inc. | TREATMENT OF MIXED DYSLIPIDEMIA |
| SI4119569T1 (sl) | 2015-11-06 | 2024-10-30 | Ionis Pharmaceuticals, Inc. | Konjugirane protismiselne spojine za uporabo v terapiji |
| EP3370708A4 (en) | 2015-11-06 | 2019-06-26 | Ionis Pharmaceuticals, Inc. | MODULATION OF APOLIPOPROTEIN (A) EXPRESSION |
| HRP20230992T1 (hr) * | 2016-02-17 | 2023-12-08 | Regeneron Pharmaceuticals, Inc. | Postupci za liječenje ili sprečavanje ateroskleroze davanjem inhibitora angptl3 |
| MX2018010401A (es) | 2016-03-03 | 2019-03-06 | Regeneron Pharma | Metodos para el tratamiento de pacientes con hiperlipidemia administrando un inhibidor de pcsk9 en combinacion con un inhibidor de angptl3. |
| EP3429690A4 (en) * | 2016-03-16 | 2019-10-23 | Ionis Pharmaceuticals, Inc. | METHOD FOR MODULATING KEAP1 |
| AU2017258105B2 (en) * | 2016-04-28 | 2024-09-05 | Regeneron Pharmaceuticals, Inc. | Methods for treating patients with familial hypercholesterolemia |
| WO2017188898A1 (en) | 2016-04-29 | 2017-11-02 | Nanyang Technological University | G-quadruplex-containing antisense oligonucleotides |
| EP3475424A1 (en) | 2016-06-22 | 2019-05-01 | ProQR Therapeutics II B.V. | Single-stranded rna-editing oligonucleotides |
| CA3035293A1 (en) | 2016-09-01 | 2018-03-08 | Proqr Therapeutics Ii B.V. | Chemically modified single-stranded rna-editing oligonucleotides |
| AU2017368050A1 (en) | 2016-11-29 | 2019-06-20 | Puretech Lyt, Inc. | Exosomes for delivery of therapeutic agents |
| CN113652431A (zh) * | 2016-12-21 | 2021-11-16 | 苏州瑞博生物技术股份有限公司 | 一种小干扰核酸和药物组合物及其用途 |
| EP3571300A1 (en) | 2017-01-19 | 2019-11-27 | ProQR Therapeutics II B.V. | Oligonucleotide complexes for use in rna editing |
| US11677246B2 (en) | 2017-08-30 | 2023-06-13 | Kyocera Corporation | Power management method and power management apparatus |
| PE20201287A1 (es) * | 2017-09-14 | 2020-11-24 | Arrowhead Pharmaceuticals Inc | Agentes de iarn y composiciones para inhibir la expresion de la angiopoyetina tipo 3 (angptl3) y metodos de uso |
| US11660347B2 (en) | 2017-12-01 | 2023-05-30 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate containing same, preparation method, and use thereof |
| JP7261494B2 (ja) | 2017-12-01 | 2023-04-20 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用 |
| CN118236391A (zh) | 2017-12-01 | 2024-06-25 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| CN110997919B (zh) | 2017-12-01 | 2024-04-02 | 苏州瑞博生物技术股份有限公司 | 双链寡核苷酸、含双链寡核苷酸的组合物与缀合物及制备方法和用途 |
| WO2019105435A1 (zh) | 2017-12-01 | 2019-06-06 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| CN110959011B (zh) | 2017-12-29 | 2023-03-28 | 苏州瑞博生物技术股份有限公司 | 缀合物及其制备方法和用途 |
| GB201808146D0 (en) | 2018-05-18 | 2018-07-11 | Proqr Therapeutics Ii Bv | Stereospecific Linkages in RNA Editing Oligonucleotides |
| EP3842534A4 (en) | 2018-08-21 | 2022-07-06 | Suzhou Ribo Life Science Co., Ltd. | NUCLEIC ACID, PHARMACEUTICAL COMPOSITION AND CONJUGATE WITH NUCLEIC ACID AND THEIR USE |
| EP3862024A4 (en) | 2018-09-30 | 2022-08-17 | Suzhou Ribo Life Science Co., Ltd. | SIRNA CONJUGATE, METHOD FOR ITS PRODUCTION AND ITS USE |
| AU2019382087B2 (en) | 2018-11-13 | 2026-02-19 | Lipigon Pharmaceuticals Ab | ANGPTL4 oligonucleotides influencing the regulation of the fatty acid metabolism |
| CN112423795A (zh) * | 2018-12-28 | 2021-02-26 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| CN112423794A (zh) | 2018-12-28 | 2021-02-26 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| EP3908287A1 (en) * | 2019-01-08 | 2021-11-17 | Avogadro Development Corp. | Treatment of fatty liver disease |
| JP7663951B2 (ja) | 2019-05-22 | 2025-04-17 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、薬物組成物及び複合体ならびに調製方法と使用 |
| CN113811613B (zh) | 2019-05-22 | 2024-04-05 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| AU2020280439B2 (en) | 2019-05-22 | 2025-08-14 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use |
| CN111973617A (zh) * | 2019-05-23 | 2020-11-24 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| WO2020238766A1 (zh) | 2019-05-24 | 2020-12-03 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| US12559551B2 (en) | 2019-05-24 | 2026-02-24 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-ANGPTL3 antibodies |
| CN116333013B (zh) * | 2020-09-30 | 2025-09-02 | 纳肽得(青岛)生物医药有限公司 | 一种靶向配体 |
| AU2022231003A1 (en) | 2021-03-04 | 2023-09-14 | Alnylam Pharmaceuticals, Inc. | Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof |
| CA3224904A1 (en) * | 2021-06-21 | 2022-12-29 | Shanghai Junshi Biosciences Co., Ltd. | Sirna inhibiting angptl3 gene expression and use thereof |
| CA3241896A1 (en) | 2021-12-22 | 2023-06-29 | Regeneron Pharmaceuticals, Inc. | Treatment of kidney diseases with angiopoietin like 3 (angptl3) inhibitors |
| WO2023134705A1 (zh) * | 2022-01-11 | 2023-07-20 | 上海金中锘美生物医药科技有限公司 | 抑制angptl3表达的rna干扰剂及其用途 |
| CN119585431A (zh) * | 2022-08-08 | 2025-03-07 | 大睿生物医药科技(上海)有限公司 | 调控ANGPTL3基因活性的siRNA分子 |
| WO2024102913A1 (en) | 2022-11-10 | 2024-05-16 | Regeneron Pharmaceuticals, Inc. | Treatment of kidney diseases with a combination of angiopoietin like 3 (angptl3) inhibitors and solute carrier family 5 member 2 (slc5a2) inhibitors |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2699808A (en) | 1944-10-06 | 1955-01-18 | Mark W Lowe | Apparatus for peeling tomatoes |
| US2699508A (en) | 1951-12-21 | 1955-01-11 | Selectronics Inc | Method of mounting and construction of mounting for low frequency piezoelectric crystals |
| US6582908B2 (en) | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
| RU95114435A (ru) | 1992-12-14 | 1997-05-20 | Ханивелл Инк. (Us) | Система с бесщеточным двигателем постоянного тока |
| US5801154A (en) | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| US5656408A (en) | 1996-04-29 | 1997-08-12 | Xerox Corporation | Coated carrier particles |
| US6770748B2 (en) | 1997-03-07 | 2004-08-03 | Takeshi Imanishi | Bicyclonucleoside and oligonucleotide analogue |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
| CA2303299C (en) | 1997-09-12 | 2016-02-23 | Exiqon A/S | Oligonucleotide analogues |
| US20030228597A1 (en) | 1998-04-13 | 2003-12-11 | Cowsert Lex M. | Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation |
| DK1123094T3 (da) * | 1998-09-15 | 2007-08-20 | Btg Int Ltd | Terapeutiske præparater (II) |
| NZ514348A (en) | 1999-05-04 | 2004-05-28 | Exiqon As | L-ribo-LNA analogues |
| US6525191B1 (en) | 1999-05-11 | 2003-02-25 | Kanda S. Ramasamy | Conformationally constrained L-nucleosides |
| AU6605900A (en) * | 1999-07-16 | 2001-02-05 | Hyseq, Inc. | Novel angiopoietin materials and methods |
| MXPA02005758A (es) * | 1999-12-09 | 2002-09-18 | Sankyo Co | Metodo para evaluar un remedio o agente preventivo para hiperlipidemia. |
| EP1403367A4 (en) | 2001-06-08 | 2005-08-17 | Sankyo Co | A MEDICAMENT TEST METHOD FOR TREATING OR PREVENTING DISEASES SUCH AS HYPERLIPEMIA |
| JP2005504020A (ja) * | 2001-07-03 | 2005-02-10 | アイシス・ファーマシューティカルス・インコーポレーテッド | ヌクレアーゼ耐性キメラオリゴヌクレオチド |
| ES2429034T3 (es) * | 2001-11-16 | 2013-11-12 | Genentech, Inc. | Uso de antagonistas de ANGPTL3 para el tratamiento de enfermedades hepáticas |
| WO2004043979A2 (en) | 2002-11-05 | 2004-05-27 | Isis Pharmaceuticals, Inc. | Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
| WO2004041889A2 (en) | 2002-11-05 | 2004-05-21 | Isis Pharmaceuticals, Inc. | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
| US7511131B2 (en) * | 2002-11-13 | 2009-03-31 | Genzyme Corporation | Antisense modulation of apolipoprotein B expression |
| JP2006507841A (ja) | 2002-11-14 | 2006-03-09 | ダーマコン， インコーポレイテッド | 機能的ｓｉＲＮＡおよび超機能的ｓｉＲＮＡ |
| WO2006006948A2 (en) | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
| WO2004072046A2 (en) | 2003-02-12 | 2004-08-26 | Carex S.A. | Quinoline derivatives and their use for modulation of lxr activity |
| WO2004106356A1 (en) | 2003-05-27 | 2004-12-09 | Syddansk Universitet | Functionalized nucleotide derivatives |
| WO2005021745A1 (ja) | 2003-08-22 | 2005-03-10 | Nihon University | 肝細胞癌に関連する遺伝子 |
| EP1661905B9 (en) | 2003-08-28 | 2012-12-19 | IMANISHI, Takeshi | Novel artificial nucleic acids of n-o bond crosslinkage type |
| JP5379347B2 (ja) | 2003-09-18 | 2013-12-25 | アイシス ファーマシューティカルズ， インコーポレーテッド | ４’−チオヌクレオシドおよびオリゴマー化合物 |
| US7468431B2 (en) * | 2004-01-22 | 2008-12-23 | Isis Pharmaceuticals, Inc. | Modulation of eIF4E-BP2 expression |
| EP1735622A2 (en) * | 2004-04-13 | 2006-12-27 | Arena Pharmaceuticals, Inc. | Modulators of human g protein-coupled receptors for the treatment of hyperglycemia and related disorders |
| EP1752536A4 (en) | 2004-05-11 | 2008-04-16 | Alphagen Co Ltd | POLYNUCLEOTIDE CAUSING RNA INTERFERENCE AND METHOD OF REGULATING GENE EXPRESSION WITH THE USE OF THE SAME |
| EP1771474B1 (en) | 2004-07-20 | 2010-01-27 | Genentech, Inc. | Inhibitors of angiopoietin-like 4 protein, combinations, and their use |
| CA2574791A1 (en) * | 2004-07-20 | 2006-02-09 | Genentech, Inc. | Compositions and methods of using angiopoietin-like 4 protein |
| WO2006034348A2 (en) | 2004-09-17 | 2006-03-30 | Isis Pharmaceuticals, Inc. | Enhanced antisense oligonucleotides |
| US20060147894A1 (en) | 2004-12-30 | 2006-07-06 | Vicam, L.P. | Jacketed vessel for holding semen for sex biasing mammals through artificial insemination and systems and methods for enhancing the probability of sex biasing using the same |
| ES2351674T3 (es) | 2006-01-27 | 2011-02-09 | Isis Pharmaceuticals, Inc. | Análogos de ácidos nucleicos bicíclicos modificados en la posición 6. |
| DK2021472T3 (da) * | 2006-05-05 | 2011-09-19 | Isis Pharmaceuticals Inc | Forbindelser og fremgangsmåder til modulering af genekspression |
| CA2651453C (en) | 2006-05-11 | 2014-10-14 | Isis Pharmaceuticals, Inc. | 5'-modified bicyclic nucleic acid analogs |
| JP2010500290A (ja) * | 2006-08-04 | 2010-01-07 | アイシス ファーマシューティカルズ， インコーポレーテッド | Ｊｎｋタンパク質を調節するための組成物および方法 |
| US8093222B2 (en) * | 2006-11-27 | 2012-01-10 | Isis Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia |
| CN101589143A (zh) * | 2006-11-27 | 2009-11-25 | Isis药物公司 | 用于治疗高胆固醇血症的方法 |
| WO2008073300A2 (en) * | 2006-12-08 | 2008-06-19 | Lexicon Pharmaceuticals, Inc. | Monoclonal antibodies against angptl3 |
| WO2008101157A1 (en) | 2007-02-15 | 2008-08-21 | Isis Pharmaceuticals, Inc. | 5'-substituted-2'-f modified nucleosides and oligomeric compounds prepared therefrom |
| CA2717618A1 (en) | 2008-03-07 | 2009-09-11 | National University Corporation University Of Toyama | Homologous recombination method, cloning method, and kit |
| JP5207355B2 (ja) | 2008-03-12 | 2013-06-12 | 凸版印刷株式会社 | 標的ヌクレオチド配列を有する核酸の検出方法、プローブセット、及び核酸の識別方法 |
| WO2009148605A2 (en) | 2008-06-04 | 2009-12-10 | Isis Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia |
| AT507215B1 (de) | 2009-01-14 | 2010-03-15 | Boehler Edelstahl Gmbh & Co Kg | Verschleissbeständiger werkstoff |
| CN111700901A (zh) * | 2010-01-08 | 2020-09-25 | Ionis制药公司 | 血管生成素样3表达的调节 |
| US9984408B1 (en) | 2012-05-30 | 2018-05-29 | Amazon Technologies, Inc. | Method, medium, and system for live video cooperative shopping |
| EP2733390B1 (en) | 2012-11-15 | 2020-05-13 | Volvo Car Corporation | Dampening structure for gear shift cables |
| US10120707B2 (en) | 2015-12-08 | 2018-11-06 | Paypal, Inc. | Deployment of development environments |
| US9778708B1 (en) | 2016-07-18 | 2017-10-03 | Lenovo Enterprise Solutions (Singapore) Pte. Ltd. | Dual sided latching retainer for computer modules |
-
2011
- 2011-01-07 CN CN202010636959.XA patent/CN111700901A/zh active Pending
- 2011-01-07 JP JP2012548193A patent/JP5822845B2/ja not_active Expired - Fee Related
- 2011-01-07 CN CN201610643333.5A patent/CN106146591B/zh not_active Expired - Fee Related
- 2011-01-07 DK DK11732249.5T patent/DK2521556T3/en active
- 2011-01-07 WO PCT/US2011/020606 patent/WO2011085271A2/en not_active Ceased
- 2011-01-07 EP EP18174926.8A patent/EP3421040A1/en not_active Withdrawn
- 2011-01-07 EP EP11732249.5A patent/EP2521556B1/en active Active
- 2011-01-07 CA CA2786071A patent/CA2786071C/en active Active
- 2011-01-07 AU AU2011203986A patent/AU2011203986C1/en not_active Ceased
- 2011-01-07 ES ES11732249.5T patent/ES2677969T3/es active Active
- 2011-01-07 CN CN201180008657.7A patent/CN102753186B/zh not_active Expired - Fee Related
- 2011-01-07 US US13/520,997 patent/US8653047B2/en active Active
-
2014
- 2014-01-07 US US14/149,715 patent/US9139831B2/en active Active
-
2015
- 2015-08-07 JP JP2015156939A patent/JP6440592B2/ja not_active Expired - Fee Related
- 2015-08-10 US US14/821,982 patent/US20160060626A1/en not_active Abandoned
-
2017
- 2017-05-18 JP JP2017098842A patent/JP2017165765A/ja active Pending
-
2018
- 2018-01-12 US US15/870,306 patent/US20180142244A1/en not_active Abandoned
-
2019
- 2019-12-20 US US16/722,043 patent/US11225664B2/en active Active
-
2020
- 2020-02-28 JP JP2020032712A patent/JP2020100654A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012029693A5 (enExample) | ||
| JP2014513954A5 (enExample) | ||
| JP2013518605A5 (enExample) | ||
| Tian et al. | Brahma‐related gene 1 bridges epigenetic regulation of proinflammatory cytokine production to steatohepatitis in mice | |
| RU2501803C2 (ru) | Композиции и способы модуляции экспрессии рецептора фактора роста фибробластов 4 (fgfr4) | |
| JP2014511686A5 (enExample) | ||
| IL264288B (en) | Methods and compositions for modulating apolipoprotein(a) expression | |
| JP2017533721A5 (enExample) | ||
| JP2017510271A5 (enExample) | ||
| FI2906696T4 (fi) | Menetelmiä c9orf72:n ilmentymisen moduloimiseksi | |
| NZ710192A (en) | Modulation of apolipoprotein ciii (apociii) expression | |
| JP2015536132A5 (enExample) | ||
| RU2015119409A (ru) | Конъюгаты олигонуклеотидов | |
| NO2019001I1 (no) | Forbindelse omfattende et modifisert oligonukleotid som har en nukleobasesekvens bestående av 20 koblede nukleosider ifølge EP B1 2563920 krav 1 (SEQ ID NO: 80), hvor det modifiserte oligonukleotidet omfatter: et avstandssegment bestående av ti koblede deoksynukleosider; et 5'-vingesegment bestående av fem koblede nukleosider; og et 3'-vingesegment bestående av fem koblede nukleosider; hvor avstandssegmentet er plassert mellom 5'-vingesegmentet og 3'-vingesegmentet, hvor hvert nukleosid av hvert vingesegment omfatter et 2'-0-metoksyetylsukker; hvor hver cytosin av det modifiserte oligonukleotid er en 5-metylcytosin, og hvor hver internukleosid-binding av det modifiserte oligonukleotid er en fosfortioatbinding; og spesielt inotersen; og dets derivater, så som dets salter, inkludert natriumsalter. | |
| JP2013226147A5 (enExample) | ||
| HRP20241138T1 (hr) | Oligonukleotidi za induciranje ekspresije očinskog ube3a | |
| JP2015507625A5 (enExample) | ||
| JP2012050438A5 (enExample) | ||
| JP2009508527A5 (enExample) | ||
| JP2017509354A5 (enExample) | ||
| JP2016096826A5 (enExample) | ||
| RU2015151200A (ru) | Композиции и способы модулирования экспрессии аполипопротеина (а) | |
| Van Gestel et al. | shRNA-induced saturation of the microRNA pathway in the rat brain | |
| HRP20130766T1 (hr) | Mikrornk (mirnk) mir-21 za dijagnostiäśke i terapijske svrhe | |
| RU2011119479A (ru) | Модуляция экспрессии фактора 11 |